Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent.

Abstract: Compositions and methods for inactivating RNA-guided genome editing systems in specific tissue, for example hepatocytes, are provided herein. In one embodiment, the compositions are small chemically modified oligonucleotides that can target and bind to guide RNA, thus eliminating the ability of guide RNA to interact with an endonuclease. The disclosed oligonucleotides are delivered in lipid nanoparticles formulated to target a specific tissue. Subsequently delivered RNA-guided genome editing systems will be inhibited in the specific tissue that received the oligonucleotides. The disclosed compositions and methods allow for reduced RNA-guided genome editing in hepatocytes.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: Described herein are compositions and methods for identifying materials suitable for delivery of an agent to a target tissue. These compositions and methods may simultaneously screen a library of materials for the ability to deliver an agent to a target. The compositions and methods may also be used to confirm that the agent is delivered in a manner sufficient for function of the agent.

Abstract: Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand are also provided.

Abstract: Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.